daxim 2.5mg/ml concentrado para solucion para perfusion
abbvie sas, sucursal del peru - levosimendan; - concentrado para solucion para perfusion - por vial 1.00 ml
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocítica, crónica, b-cell - agentes antineoplásicos - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
xydalba
abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - antibacterianos para uso sistémico, - tratamiento de infecciones bacterianas agudas de la piel y de la estructura de la piel (absssi) en adultos.
moderiba 200 mg tabletas recubiertas
abbvie pharmaceuticals s.c.a. - ribavirina - tabletas recubiertas - 200 mg
lupron depot pds 30 mg polvo y disolvente para suspension inyectable
abbvie sas, sucursal del peru - droguerÍa - polvo y disolvente para suspension inyectable - por jeringa precargada - - leuprorelina
humira ac 40mg/0.4ml solucion inyectable
abbvie sas, sucursal del peru - droguerÍa - adalimumab - solucion inyectable - 40mg/0.4ml - por mililitro ml - - adalimumab
skyrizi 75mg /0.83ml solucion inyectable
abbvie sas, sucursal del peru - droguerÍa - risankizumab - solucion inyectable - 75mg/0.83ml - por mililitro 0.83 ml - - risankizumab
humira®ac
abbvie deutschland gmbh & co. kg [de] germany - adalimumab 40 mg - solucion inyectable - cada 0,4 ml de solución contiene: adalimumab 40 mg
lupron® depot 11.25 mg polvo liofilizado para reconstituir a suspensión inyectable
abbvie inc. estados unidos - acetato de leuprolida/acetato de leuprorelina 11.25 mg - polvo y solvente para suspensiÓn inyectable - cada jeringa prellenada (cámara frontal) contiene: acetato de leuprolida/acetato de leuprorelina 11.25 mg
lupron depot 3.75 mg
abbvie inc. estados unidos - acetato de leuprolida 3.75mg - polvo esteril para reconstituir a suspension inyectable - cada jeringa prellenada (cámara frontal) contiene: acetato de leuprolida 3.75 mg